3rd International AIDS Society Conference on HIV Pathogenesis and Treatment Rio de Janeiro - July 24 - 27, 2005

INITIATION OF ARV TREATMENT IN THE REPUBLIC OF ARMENIA

IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd: Abstract No. MoPe11.4C01

Grigoryan S., Hakobyan A., Papoyan A., Hovhannisyan E.
National Center for AIDS Prevention, Yerevan, Armenia

INTRODUCTION: From 1988 to 1 February 2005 305 HIV cases were registered in the Republic of Armenia. Until 2005 ARV treatment has been inaccessible for PLWHA in the country. The National Programme on HIV/AIDS Prevention (supported by the GFATM) envisages treatment for 20 PLWHA. In 2004 the National HIV/AIDS Treatment and Care Protocols were developed and ratified on the basis of HIV/AIDS Treatment and Care Protocols for CIS countries developed by WHO. The National Protocols recommend that PLWHA should start ARV treatment when clinical AIDS stage is present, CD4+ <200/µl or CD4+ <350/µl in symptomatic patients. In order to identify HIV patients having indications for starting ARV treatment 74 PLWHA were tested and examined.

METHODS: The study was conducted in the National Center for AIDS Prevention. Full scale clinical, instrumental examinations and laboratory tests (CD4+ T-lymphocyte, Hepatitis-B and C) are performed during initial evaluation of PLWHA to identify the stage of the disease, to diagnose comorbidities and opportunistic diseases, to provide primary prevention of opportunistic infections and to identify the necessity of ARV therapy. PLWHA with indications for ARV treatment underwent blood biochemical testing.

RESULTS: 74 PLWHA have been tested, 21 of which have CD4+ <200/µl , 6 have Hepatitis-B, 29 - Hepatitis-C, and 9 are co-infected with both infections. After clinical examination it is turned out that 7 patients have oral candidosis, 5 have herpes simplex, 4 have tuberculosis, 2 have coccidioidomycosis, 1 have cryptococcosis, 1 have MAC.

CONCLUSIONS: Analysis of the data of these 21 patients has shown, that average duration of the disease from the time of possible infection is 5.4 years, and it is noteworthy that 2/3 of them are injecting drug users. The study results allow identifying those PLWHA who are currently in need of ARV treatment and forecast those who will need ARV treatment in the near future.

Download PDF of this abstract.

050724
Clinical | MoPe11.4C01 | Samvel Grigoryan
Strategies for delivery

Copyright © 2005 - International AIDS Society (IAS). All information and content relating to the abstracts from the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.